Literature DB >> 23314231

Improvement in visual acuity and contrast sensitivity in patients with central serous chorioretinopathy after macular subthreshold laser therapy.

Mehdi Behnia1, Mehdi Khabazkhoob, Soheil Aliakbari, Arash E Abadi, Hassan Hashemi, Pupak Pourvahidi.   

Abstract

PURPOSE: The purpose of the study was to measure the improvement in vision and contrast sensitivity in patients with central serous chorioretinopathy after macular subthreshold laser therapy.
METHODS: Cases included in this clinical trial were patients diagnosed with acute central serous chorioretinopathy less than 1 month in duration. Each patient was randomized to either observation group or treatment group with subthreshold argon laser. First and sixth month of follow-up results were then recorded, and visual improvement and contrast sensitivity were compared between the two groups.
RESULTS: Of 37 patients with central serous chorioretinopathy, 25 were men and 12 were women with a mean age of 38.6 ± 5.9 years. At 6 months, mean best-corrected visual acuity improved from 0.26 to 0.03 logarithm of the minimum angle of resolution in the laser group and from 0.12 to 0.04 logarithm of the minimum angle of resolution in the observation group (P < 0.001). Except spatial frequencies of 18 cycles per degree (P = 0.207), the contrast sensitivity in spatial frequencies of 3, 6, and 12 cycles per degree was significantly more favorable in the laser group during the first and sixth month.
CONCLUSION: Treatment of patients with acute central serous chorioretinopathy with subthreshold laser improved the best-corrected visual acuity and contrast sensitivity compared with those in the observation group. The laser group also showed a more rapid improvement. In both groups, best-corrected visual acuity improved in most patients after 6 months; however, the contrast sensitivity was significantly better in the treatment group.

Entities:  

Mesh:

Year:  2013        PMID: 23314231     DOI: 10.1097/IAE.0b013e3182670fa3

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  14 in total

1.  Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR).

Authors:  Tina Rike Herold; Kristina Rist; Siegfried Georg Priglinger; Michael Werner Ulbig; Armin Wolf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-07-31       Impact factor: 3.117

2.  Comparison of photodynamic therapy and navigated microsecond laser for chronic central serous chorioretinopathy.

Authors:  Cyprian Gabriel Ntomoka; Bindu Rajesh; Gachago Muchai Muriithi; Abhilash Goud; Jay Chhablani
Journal:  Eye (Lond)       Date:  2018-02-12       Impact factor: 3.775

3.  Spironolactone in the treatment of central serous chorioretinopathy - a case series.

Authors:  T R Herold; K Prause; A Wolf; W J Mayer; M W Ulbig
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-20       Impact factor: 3.117

4.  Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.

Authors:  Brian E Goldhagen; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2017-05-08

5.  OCT biomarkers related to subthreshold micropulse laser treatment effect in central serous chorioretinopathy.

Authors:  Fang Zheng; Jingliang He; Zhitao Su; Ye Liu; Yufeng Xu; Lei Liu; Panpan Ye
Journal:  BMC Ophthalmol       Date:  2022-06-07       Impact factor: 2.086

6.  Application of subthreshold laser therapy in retinal diseases: a review.

Authors:  Spencer M Moore; Daniel L Chao
Journal:  Expert Rev Ophthalmol       Date:  2018-12-11

Review 7.  Interventions for central serous chorioretinopathy: a network meta-analysis.

Authors:  Mahsa Salehi; Adam S Wenick; Hua Andrew Law; Jennifer R Evans; Peter Gehlbach
Journal:  Cochrane Database Syst Rev       Date:  2015-12-22

8.  Pattern of Contrast Sensitivity Changes in Acute Central Serous Chorioretinopathy.

Authors:  Preeyachan Lourthai; Patama Bhurayanontachai
Journal:  J Ophthalmol       Date:  2017-12-20       Impact factor: 1.909

9.  Oral Spironolactone versus Conservative Treatment for Non-Resolving Central Serous Chorioretinopathy in Real-Life Practice.

Authors:  Suthasinee Sinawat; Watcharaporn Thongmee; Thuss Sanguansak; Wipada Laovirojjanakul; Supat Sinawat; Yosanan Yospaiboon
Journal:  Clin Ophthalmol       Date:  2020-06-24

10.  Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy.

Authors:  Ahmed Hosni Abd Elhamid
Journal:  Clin Ophthalmol       Date:  2015-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.